17 November 2026 Morning

ChatGPT

Market Pulse

The common question this morning is less whether belief in AI has ended than who will finance its growth, and on what terms. Broad equity selling combines with high interest rates, cash being raised for a new IPO and lower long-range spending forecasts. Against that, narrow areas such as lasers, server memory and reliable power connections may still face strong demand. Applying the same growth or loss rate to every AI company misses those differences.

Today’s NVIDIA results are an important test of that distinction. The Megaspeed chronology reported overnight challenges accounts that treat older events as new, but does not clear a company or individual of every allegation. More concrete than leadership rumours are the company’s forward sales expectations and how its customers will pay for investment. Strong Anthropic interest also does not mean final allocation or immediate cash for the entire infrastructure chain.

Digital resilience is the second major theme. Optimizely’s reported malicious-code incident and Google’s autonomous-attack research point to real security problems, while later Chase and United accounts describe technical disruptions. Combining all of them into one attack would be wrong. The more useful investment question is which company can turn outage, financing and delivery risks into real contracts, operating capacity and profitable sales.

Sectors and assets

Sector and asset interpretation
AreaTone of the postsMy interpretationWhat would change this view?
Global equitiesNegative

Technology-heavy indices look more vulnerable. Relative resilience in equal-weight or less AI-exposed markets suggests rotation within markets as well as risk reduction. Relative strength is not the same as a positive return.

Company earnings expectations, a broadening recovery and the bond market’s response to selling.

AI chips and NVIDIAMixed

Chip demand and the risk of holding the shares are different questions. Lower spending forecasts and leadership uncertainty weigh on prices while the industry-leadership argument persists. The latest Megaspeed account changes the chronology, not an official clearance or reinstatement decision.

NVIDIA’s results today, forward outlook and explanations of customer financing.

Memory and photonicsMixed

More data moving within each server can support lasers and fast memory. NAND, phone memory and optical modules nevertheless face different cycles. A shortage in one product does not protect every supplier’s price or profit.

Product-level orders and prices, customer qualifications, capacity additions and actual optical-product deliveries.

AI cloud and data centresNegative

Announced megawatts or multiyear contract totals are not yet revenue. SHAZ results and project delays highlight the separate steps of power access, customer acceptance and billing. Concentrated option positions make that waiting period riskier.

Capacity entering service, binding leases, customer acceptance, collections and available cash.

AI labs and IPOsMixed

Anthropic’s proposed offering attracts attention, but a range is not a final price and an order is not an allocation. Reported future compute commitments and stock-based compensation are different items; counting all of them as cash spent today distorts the picture.

Final prospectus and price, allocations, financing conditions and revenue versus cost per unit of use.

CybersecurityMixed

Always-on attack tools may require automation in defence too. That is a potential software and compute opportunity, but insufficient to call every outage an attack or every security stock a winner. United’s later resolution statement is narrower than the initial panic headlines.

Post-incident technical findings, renewed security budgets and actual customer wins.

Power and electrical equipmentMixed

PJM’s proposal seeks to make data centres ride through brief grid disturbances. That could create equipment demand; approval and an order are still different things. The weak Capstone results described in the feed also show that a strong sector story does not become sales at every supplier.

Regulatory approval, binding data-centre orders, service costs and delivered equipment.

Oil and shippingMixed

Attack claims do not automatically lift oil. Returning production, demand expectations and the dollar act together. Refiners can also face different profitability in gasoline, diesel and jet fuel; crude prices alone do not explain every company’s earnings.

Actual strait transits, production and inventories, freight rates and product-level refining margins.

Gold, silver and industrial metalsMixed

A small morning rise in gold and silver does not establish that the larger decline has ended. Chinese construction demand and steel exports create a separate industrial-metals dynamic. A precious metal’s safe-haven role and its daily price move may operate over different horizons.

The dollar and real yields, physical demand, China’s production-consumption balance and whether the rebound persists.

Rates and the dollarNegative

Costlier debt can lower the present value of projects whose revenue is expected years ahead. The Fed modelling AI risks is not a definite crash forecast. Sticky inflation and slower growth can coexist, making reliance on one rate scenario difficult.

The breadth of inflation, employment, credit conditions and actual Federal Reserve decisions.

Bitcoin and cryptoMixed

Historically strong quarters or earlier highs do not have to stop today’s decline. Some accounts seek a leveraged bounce while others close profitable bearish trades. Closing a short is not the same as adopting a long-term bullish view.

Fund flows, leveraged liquidations, carrying costs and spot-market demand.

BiotechnologyMixed

The drug portfolio, clinical success and debt need joint assessment. The 0.32 hazard ratio cited for CGON does not mean 68% of patients were cured; it describes relative event risk within a particular trial. Even a strong result is not automatic approval or profitable sales.

Full trial data, safety findings, regulatory decisions, drug sales and cash needs.